Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

For this year, Tempus AI, Inc. (NASDAQ:TEM) expects full-year revenue of approximately $1.24 billion for the consolidated TEM and Ambry Genetics business, which represents approximately 79 percent ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on TEM stock.

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...

Tempus AI reports mixed fourth-quarter financial results. JPMorgan analyst Rachel Vatnsdal downgrades Tempus AI from Overweight to Neutral following the company's quarterly results. Every week ...

Tempus AI demonstrated strong performance in Q4 2024 with a significant revenue increase of 35.8% compared to the previous year. This growth was supported by strategic initiatives such as the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financia ...